JOSEPHINE PHAM: Open Payments
NPI 1073692489 · SAN JOSE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,718 in 68 payments from 17 companies in 2025. Trend: 2023 $1,679 · 2024 $1,617 · 2025 $1,718
Food & beverage: $1,648Education: $70
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $307 |
| Astellas Pharma US Inc | 6 | $210 |
| ABBVIE INC. | 13 | $181 |
| Novo Nordisk Inc | 10 | $180 |
| Eisai Inc. | 3 | $178 |
| Amgen Inc. | 6 | $151 |
| Lilly USA, LLC | 5 | $128 |
| GlaxoSmithKline, LLC. | 5 | $104 |
| Exact Sciences Corporation | 3 | $71 |
| SANOFI-AVENTIS U.S. LLC | 1 | $36 |
Products named: Leqembi, FASENRA, Veozah, FARXIGA, EVENITY, NUCALA, VRAYLAR, Ozempic.
Industry payments across CA — which companies pay providers there.
